Funded Project Details - FY2021
|Title:|| High-dose Testosterone in Men with Metastatic Castration-resistant Prostate Cancer and ATM or CDK12 deficiency|
Robert B. Montgomery
|Congressional District Code:
||Clinical Science R&D
|| April 2021 -
|FY 2021 Funding Amount:
|Total Award Amount
View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER
Abstract Advanced prostate cancer is a universally lethal disease and one for which no biomarkers have yet been found to inform therapeutic decision making. DNA repair deficiency in the homologous recombination and CDK12 pathways increases sensitivity of tumors to the DNA damaging effects of high dose testosterone based on early biomarker interrogations of phase II high dose testosterone studies. High dose testosterone is also very well tolerated in appropriately selected patient populations who...
Questions about the R&D website? Email the Web Team
Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.